Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20090204173 A1
Publication typeApplication
Application numberUS 12/264,836
Publication date13 Aug 2009
Filing date4 Nov 2008
Priority date5 Nov 2007
Also published asCA2704564A1, DE202008018506U1, DE202008018561U1, DE202008018604U1, EP2207587A1, EP2207587A4, EP2207587B1, EP2630984A1, EP2630984B1, EP2853285A1, EP2853285B1, EP3156099A1, US8768472, US8774926, US20130096643, US20130096644, US20130211487, US20140163660, WO2009061813A1, WO2009061813A9
Publication number12264836, 264836, US 2009/0204173 A1, US 2009/204173 A1, US 20090204173 A1, US 20090204173A1, US 2009204173 A1, US 2009204173A1, US-A1-20090204173, US-A1-2009204173, US2009/0204173A1, US2009/204173A1, US20090204173 A1, US20090204173A1, US2009204173 A1, US2009204173A1
InventorsZi-Ping Fang, Anthony V. Caparso, Brain J. Erickson
Original AssigneeZi-Ping Fang, Caparso Anthony V, Erickson Brain J
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Multi-Frequency Neural Treatments and Associated Systems and Methods
US 20090204173 A1
Abstract
Multi-frequency neural treatments and associated systems and methods are disclosed. A method in accordance with a particular embodiment includes at least reducing patient pain by applying a first electrical signal to a first target location of the patient's spinal cord region at a frequency in a first frequency range of up to about 1,500 Hz, and applying a second electrical signal to a second target location of the patient's spinal cord region at a frequency in a second frequency range of from about 2,500 Hz to about 100,000 Hz.
Images(20)
Previous page
Next page
Claims(31)
1. A method for treating patient pain, comprising:
at least reducing patient pain by:
applying a first electrical signal to a first target location of the patient's spinal cord region at a frequency in a first frequency range of up to about 1,500 Hz; and
applying a second electrical signal to a second target location of the patient's spinal cord region at a frequency in a second frequency range of from about 2,500 Hz to about 100,000 Hz.
2-14. (canceled)
15. A method for treating patient pain, comprising:
inducing paresthesia in the patient by applying a first electrical signal to a dorsal column of the patient's spinal cord region at a frequency in a first frequency range of from about 40 Hz to about 500 Hz; and
at least partially blocking patient discomfort resulting from the first electrical signal by applying a second electrical signal to at least one of a dorsal root and a dorsal root ganglion of the patient's spinal cord region at a frequency in a second frequency range of from about 2,500 Hz to about 100,000 Hz.
16. (canceled)
17. (canceled)
18. A method for treating patient pain, comprising:
implanting a first electrode proximate to a dorsal column of the patient's spinal cord region;
implanting a second electrode proximate to at least one of a dorsal root and a dorsal root ganglion of the patient's spinal cord region;
applying a first electrical signal to the first electrode at a frequency in a first frequency range of up to about 1,500 Hz; and
if the patient experiences discomfort, applying a second electrical signal to the second electrode at a frequency in a second frequency range of from about 2,500 Hz to about 20,000 Hz, in combination with applying the first electrical signal, and without repositioning the first electrode.
19-24. (canceled)
25. A system for treating patient pain, comprising:
a controller having instructions for directing first electrical signals in a first frequency range of up to about 1,500 Hz, and a generating second electrical signals in a second frequency range of from about 2,500 Hz to about 100,000 Hz;
a first electrical signal delivery device electrically coupled to the controller to receive the first electrical signals and configured to be positioned proximate to a first target location of the patient's spinal cord region; and
a second electrical signal delivery device electrically coupled to the controller to receive the second electrical signals and configured to be positioned proximate to a second target region of the patient's spinal cord region.
26-29. (canceled)
30. The system of claim 25 wherein the controller has instructions for directing the second signal at a first frequency and a first amplitude and wherein the controller further has with instructions for:
decreasing the frequency of the second signal from the first frequency to a second frequency less than the first frequency; or
decreasing the amplitude of the second signal from the first amplitude to a second amplitude less than the first amplitude; or
both decreasing the frequency of the second signal from the first frequency to the second frequency and decreasing the amplitude of the second signal from the first amplitude to the second amplitude.
31-36. (canceled)
37. A method of managing chronic pain of a patient, comprising:
applying a first signal to a first section of nerve tissue of a spinal region of the patient to increase or initiate neural activity at the first section of nerve tissue, the first section of nerve tissue being located at a dorsal column of the patient, the first signal having a frequency within a first frequency range of up to about 1,500 Hz; and
applying a second signal to a second section of nerve tissue of the spinal region to at least partially block neural activity at the second section of nerve tissue, the second section of nerve tissue being located at the dorsal column of the patient, the second signal having a frequency within a second frequency range of about 2,500 Hz to about 100,000 Hz.
38-50. (canceled)
51. A method for treating patient pain, comprising:
at least reducing patient back pain by:
applying a first electrical signal to the patient's spinal cord region at a frequency in a first frequency range of up to about 1,500 Hz; and
applying a second electrical signal to the patient's spinal cord region at a frequency in a second frequency range of from about 2,500 Hz to about 100,000 Hz.
52. The method of claim 51 wherein applying the first electrical signal includes applying the first electrical signal to a first target location of the patient's spinal cord region, and wherein applying the second electrical signal includes applying the second electrical signal to a second target location of the patient's spinal cord region.
53. The method of claim 52 wherein the first and second target locations are different.
54. The method of claim 52, wherein the first target location is at a dorsal column of the patient's spinal cord region, and the second target location is at least one of a dorsal root and a dorsal root ganglion of the patient's spinal cord region.
55. The method of claim 51 wherein the first and second electrical signals are both applied to the dorsal column.
56. The method of claim 55 wherein the first electrical signal is applied to a first target location at the dorsal column and then second electrical signal is applied to a second target location at the dorsal column, the second location being different than the first location.
57. The method of claim 51 wherein applying the second electrical signal includes applying the second electrical signal in a second frequency range of from about 3,000 Hz to about 10,000 Hz.
58. The method of claim 51, further comprising inducing paresthesia by applying the first electrical signal.
59. The method of claim 51, further comprising at least partially blocking patient discomfort by applying the second electrical signal.
60. The method of claim 51, further comprising at least partially blocking patient discomfort resulting from applying the first electrical signal by applying the second electrical signal.
61. A method for treating patient pain, comprising:
at least partially inhibiting sensation signals associated with one or more selected regions of a patient's body, without decreasing or eliminating the transmission of motor control impulses, by applying a therapy signal at a frequency of from about 2,500 Hz to about 100,000 Hz, with the therapy signal preferentially affecting dorsally located neural structures within the patient's dura mater at the patient's spinal cord region.
62. The method of claim 61 wherein applying a therapy signal includes applying the therapy signal without producing paresthesia.
63. The method of claim 61 wherein applying a therapy signal includes applying a therapy signal to the patient's dorsal root.
64. The method of claim 61 wherein applying a therapy signal includes applying a therapy signal to the patient's dorsal root ganglion.
65. The method of claim 61 wherein applying a therapy signal includes applying a therapy signal to the patient's dorsal column.
66. The method of claim 61 wherein at least partially inhibiting sensation signals includes blocking pain signals.
67. The method of claim 61 wherein applying a therapy signal includes applying a therapy signal having a frequency of from about 2,500 Hz to about 20,000 Hz.
68. The method of claim 61 wherein applying a therapy signal includes applying a therapy signal having a frequency of from about 3,000 Hz to about 10,000 Hz.
Description
    CROSS-REFERENCE TO RELATED APPLICATION
  • [0001]
    The present application claims priority to U.S. Provisional Application 60/985,353, filed Nov. 5, 2007 and incorporated herein by reference.
  • TECHNICAL FIELD
  • [0002]
    The present disclosure relates generally to methods and apparatuses for treating patient conditions, including chronic pain conditions via techniques that can include stimulating and blocking neuronal tissue associated with the spinal cord.
  • BACKGROUND A. Neural Stimulation Treatments
  • [0003]
    Existing patient treatments include applying stimulation (e.g., up-regulating) signals to nerves, muscles or organs for treating a wide variety of medical disorders. Stimulation signal parameters (e.g., pulse width, frequency, and amplitude) are selected to initiate neural action potentials to be propagated along the nerve to an organ (e.g., brain or stomach).
  • [0004]
    Down-regulating signals also can be applied to nerve fibers. Certain signal parameters can result in a signal that inhibits the nerve or blocks the propagation of action potentials along the nerve. In general, the nerve conduction block is applied to nerves with down-regulating signals selected to block the entire cross-section or part of the cross section of the nerves (e.g., afferent, efferent, myelinated, and non-myelinated fibers) at the site where the down-regulating signal is applied.
  • [0005]
    In some systems, down-regulating signals are used to manage motor control over certain areas of a patient's body. For example, cryogenic nerve blocking of the vagus nerve to control motor activity is described in Dapoigny et al., “Vagal influence on colonic motor activity in conscious nonhuman primates,” Am. J. Physiol., 262: G231-G236 (1992). A cryogenic vagal block and the resulting effect on gastric emptying are described in Paterson Calif., et al., “Determinants of Occurrence and Volume of Transpyloric Flow During Gastric Emptying of Liquids in Dogs: Importance of Vagal Input,” Dig Dis Sci, (2000); 45:1509-1516.
  • B. Application to Chronic Pain
  • [0006]
    Applying up-regulating electrical energy to the spinal cord for the purpose of managing pain has been actively practiced since the 1960s. While a precise understanding of the interaction between the applied electrical energy and the nervous tissue is not fully appreciated, it is known that application of an electrical field to spinal nervous tissue can effectively mask certain types of pain transmitted from regions of the body associated with the stimulated tissue. Such spinal cord stimulation (SCS) for the treatment of chronic intractable pain was introduced by Shealy et al. (Anesth. Analg., 46, 489-491, 1967).
  • [0007]
    More specifically, applying up-regulating electrical pulses to the spinal cord associated with regions of the body (e.g., dermatomes) afflicted with chronic pain can induce paresthesia, or a subjective sensation of numbness or tingling, in the afflicted bodily regions. This paresthesia can effectively mask the non-acute pain sensations perceived at the brain.
  • [0008]
    Electrical energy, similar to that used to inhibit pain perception, also may be used to manage the symptoms of various motor disorders, for example, tremor, dystonia, spasticity, and the like. Motor spinal nervous tissue (e.g., nervous tissue from ventral nerve roots) transmits muscle/motor control signals. Sensory spinal nervous tissue (e.g., nervous tissue from dorsal nerve roots) transmits pain signals, as well as other sensory signals and proprioceptive signals.
  • [0009]
    Corresponding dorsal and ventral nerve roots depart the spinal cord “separately.” Laterally from the spinal cord, the nervous tissue of the dorsal and ventral nerve roots are mixed, or intertwined. Accordingly, electrical stimulation intended to manage and control one condition (e.g., pain) can inadvertently interfere with nerve transmission pathways in adjacent nervous tissue (e.g., motor nerves).
  • [0010]
    Electrical energy is conventionally delivered through electrodes positioned on the dorsal column external to the dura layer surrounding a spinal cord. The electrodes are typically carried by a percutaneous lead, although a laminotomy lead also can be used. Percutaneous leads commonly have two or more electrodes and are positioned within an epidural space through the use of an insertion, or Touhy-like, needle. An example of an eight-electrode percutaneous lead is an OCTRODEŽ lead manufactured by Advanced Neuromodulation Systems, Inc. of Plano, Tex. Operationally, the insertion needle is passed through the skin, between the desired vertebrae, and into an epidural space located between a dural layer and the surrounding vertebrae. The stimulation lead is fed through the bore of the insertion needle and into the epidural space. Laminotomy leads generally have a wider, paddle-like shape, and are inserted via an incision rather than through a needle. For example, a small incision is made in the back of a patient to access the space between the dura and the surrounding vertebrae.
  • [0011]
    According to the “gate-control” theory of Melzak and Wall, (Science, 150, 971-978, 1965), the suppression of pain sensations, accompanied by paresthesia, results from the activation of large cutaneous afferents (Aap fibers). Because these nerve fibers are part of the dorsal root (DR) fiber that ascends in the dorsal column (DC), paresthetic sensations can be evoked by both DC and DR stimulation.
  • [0012]
    The potential paresthesia coverage will strongly differ, however, depending on whether DC fibers or DR fibers are stimulated. When stimulating the DC fibers, the fibers corresponding to all dermatomes from the sacral ones up to the electrode level may be activated, thus resulting in broad paresthesia coverage. When stimulating DR fibers, however, the fibers will be activated in a limited number of rootlets close to the cathodal contact(s), thereby resulting in a paresthesia effect confined to one or two dermatomes at each body side.
  • [0013]
    There are several problems with existing Spinal Cord Stimulation (SCS) therapy techniques. One is the difficulty of obtaining a permanent optimal position of the lead(s), to cover the painful dermatomes with paresthesia. Another problem is the usually small range of stimulation amplitudes between the perception threshold (i.e., the threshold at which paresthesia is effected) and the discomfort threshold (i.e., the threshold at which the patient experiences pain or other discomfort), often preventing a complete coverage of the painful area by the paresthesia needed for maximum therapeutic effect (Holsheimer, Neurosurgery, 40, 5, 990-999, 1997).
  • SUMMARY
  • [0014]
    In some cases, low frequency signals are applied to the dorsal column to address chronic patient pain associated with a peripheral site. However, the dorsal roots also can be stimulated when low frequency stimulation is applied to the dorsal column to produce the paresthesia necessary to overcome the chronic pain. For example, the dorsal roots may be stimulated if the stimulation leads are placed too close to the dorsal root, and/or if the amplitude of the low frequency signal is increased to the discomfort threshold. The discomfort threshold at the dorsal root can be reached before the parethesia threshold (i.e., the threshold at which paresthesia is affected) is reached at the dorsal column. Hence, the clinician has limited freedom to increase the amplitude of the signal at the dorsal column to achieve the desired paresthesia effect, before discomfort is felt due to the dorsal root stimulation.
  • [0015]
    Aspects of the present disclosure are directed to managing chronic pain through the application of electrical energy to selected nervous tissue and, in particular embodiments, to methods and systems for treating chronic pain by applying neuromodulation therapies to one or more regions of neuronal tissue in the spinal region. As the term is used herein, the “spinal region” includes the nerves of the dorsal column, dorsal roots, and the dorsal roots ganglion, which are located within the dural layer.
  • [0016]
    A method for treating patient pain in accordance with a particular embodiment includes applying a first electrical signal to a first target location (e.g., a dorsal column) of the patient's spinal cord region at a frequency in a first frequency range of up to about 1,500 Hz. The method further includes applying a second electrical signal to a second target location (e.g., at least one of a dorsal root and a dorsal root ganglion) of the patient's spinal cord region at a frequency in a second frequency range of from about 2,500 Hz to about 100,000 Hz. In particular embodiments, the second frequency range can be from about 2,500 Hz to about 20,000 Hz, or about 3,000 Hz to about 10,000 Hz. Further embodiments include inducing paresthesia by applying the first electrical signal, and at least partially blocking patient discomfort resulting from applying the first electrical signal by applying the second electrical signal.
  • [0017]
    A method in accordance with another embodiment includes implanting a first electrode proximate to a dorsal column of the patient's spinal cord region, and implanting a second electrode proximate to at least one of a dorsal root and a dorsal root ganglion of the patient's spinal cord region. The method can further include applying a first electrical signal to the first electrode at a frequency in a first frequency range of up to about 1,500 Hz. If the patient experiences discomfort, a second electrical signal is applied to the second electrode at a frequency in a second frequency range of from about 2,500 Hz to about 100,000 Hz in combination with applying the first electrical signal, and without repositioning the first electrode. In particular embodiments, the second frequency range can be from about 2,500 Hz to about 20,000 Hz, or about 3,000 Hz to about 10,000 Hz.
  • [0018]
    Further embodiments are directed to systems for treating patient pain. In a particular embodiment, the system can include a controller having instructions for directing first electrical signals in a first frequency range of up to about 1,500 Hz, and directing second electrical signals in a second frequency range of from about 2,500 Hz to about 100,000 Hz. In particular embodiments, the second frequency range can be from about 2,500 Hz to about 20,000 Hz, or about 3,000 Hz to about 10,000 Hz. A first electrical signal delivery device can be electrically coupled to the controller to receive the first electrical signals, and can be configured to be positioned proximate to a first target location of the patient's spinal cord region (e.g., the dorsal column). A second electrical signal delivery device can be electrically coupled to the controller to receive the second electrical signals, and can be configured to be positioned proximate to a second target location of the patient's spinal cord region (e.g., at least one of a dorsal root and a dorsal root ganglion of the patient's spinal cord region).
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0019]
    FIG. 1 is a schematic diagram of an implantable spinal stimulator with an electrode array applied to the spine in accordance with an embodiment of the present disclosure.
  • [0020]
    FIG. 2 is a schematic diagram of an implantable spinal stimulator with percutaneous leads and electrodes applied to the spine in accordance with another embodiment of the present disclosure.
  • [0021]
    FIG. 3 is a partially schematic cross-sectional view of a spinal column taken along line 3-3 of FIG. 1 in accordance with an embodiment of the present disclosure.
  • [0022]
    FIG. 4 illustrates examples of biphasic, charge balanced, square wave pulses applied to electrodes on different channels of a therapy system in accordance with an embodiment of the present disclosure.
  • [0023]
    FIG. 5 illustrates examples of biphasic, charge balanced, sinusoidal wave pulses applied to electrodes on different channels of a therapy system in accordance with an embodiment of the present disclosure.
  • [0024]
    FIG. 6 is a schematic depiction of an example blocking signal applied to the dorsal column in accordance with an embodiment of the present disclosure.
  • [0025]
    FIG. 7 is a schematic depiction of an example high frequency (HF) blocking signal applied to the dorsal root in accordance with an embodiment of the present disclosure.
  • [0026]
    FIG. 8 schematically depicts the amplitude of an example low frequency (LF) stimulation signal likely to induce paresthesia, and the amplitude of the LF stimulation signal likely to induce patient discomfort at a given electrode spacing in accordance with an embodiment of the present disclosure.
  • [0027]
    FIG. 9 is a schematic view of an HF blocking signal applied to the dorsal root of a patient and an LF stimulating signal applied to the dorsal column in accordance with an embodiment of the present disclosure.
  • [0028]
    FIG. 10 is a schematic diagram of an example blocking signal, which has an amplitude that is gradually increased to an operating amplitude over a finite period of time in accordance with an embodiment of the present disclosure.
  • [0029]
    FIG. 11A is a schematic graph generally showing the changes in frequency during application of a therapy in accordance with an embodiment of the present disclosure.
  • [0030]
    FIG. 11B is a schematic graph generally showing the changes in amplitude during application of the therapy of FIG. 11A in accordance with an embodiment of the present disclosure.
  • [0031]
    FIG. 11C is a schematic graph generally showing the changes in charge/phase during application of the therapy of FIG. 11A in accordance with an embodiment of the present disclosure.
  • [0032]
    FIG. 12 is a schematic depiction of an example blocking signal initially having a high frequency (e.g., about 30-50 KHz) and a high amplitude (e.g., about 15-20 mA) in accordance with an embodiment of the present disclosure.
  • [0033]
    FIG. 13 shows the blocking signal of FIG. 12 with an initial ramp-up period in accordance with an embodiment of the present disclosure.
  • [0034]
    FIG. 14 is a schematic depiction of an example LF signal and an example HF signal indicating a representative timing strategy for applying the LF and HF signals in accordance with an embodiment of the present disclosure.
  • [0035]
    FIGS. 15-18 are schematic block diagrams of representative electrode arrays including four electrodes implanted at the spinal cord of a patient in accordance with an embodiment of the present disclosure.
  • [0036]
    FIG. 19A is a schematic block diagram of a lead configuration in which first and second percutaneous leads are implanted within the patient together in accordance with an embodiment of the present disclosure.
  • [0037]
    FIG. 19B is a schematic block diagram of a lead configuration in which a first percutaneous lead is implanted within the patient adjacent the dorsal column and a second percutaneous lead is implanted within the patient adjacent the dorsal root in accordance with an embodiment of the present disclosure.
  • [0038]
    FIG. 19C is a partially schematic illustration of percutaneous leads positioned at lumbar locations in accordance with embodiments of the disclosure.
  • [0039]
    FIG. 20 is a schematic block diagram of a multi-channel, percutaneous lead arrangement having first and second leads configured to deliver multiple therapy signals to a dorsal column of a patient in accordance with an embodiment of the present disclosure.
  • [0040]
    FIG. 21 is a schematic block diagram of a multi-channel, percutaneous lead arrangement having first and second leads configured to deliver multiple therapy signals to a dorsal root of a patient in accordance with an embodiment of the present disclosure.
  • [0041]
    FIG. 22 illustrates a first treatment signal being applied to nerves of a dorsal column of a patient in accordance with an embodiment of the present disclosure.
  • DETAILED DESCRIPTION
  • [0042]
    FIG. 1 schematically illustrates a representative therapy system 100 for providing relief from chronic pain, arranged relative to the general anatomy of a spinal cord SC of a patient. The therapy system 100 can include a controller (e.g., a pulse generator 101) implanted subcutaneously within the patient. The pulse generator 101 is attached via a lead body 102 to an electrode array 103 or other signal delivery device, which is implanted in close proximity to the spinal cord SC. The electrode array 103 can include multiple electrodes or electrode contacts carried by a support substrate. The pulse generator 101 or other controller transmits instructions and power to the electrode array 103 via the lead body 102 to apply therapy signals (e.g., electrical impulses) to the nerve fibers of the patient to up-regulate (e.g., stimulate) and/or down-regulate (e.g., block or partially block) the nerves. Accordingly, the pulse generator 101 can include a computer-readable medium containing the instructions. The pulse generator 101 and/or other elements of the system 100 can include one or more processors, memories and/or input/output devices. The pulse generator 101 can include multiple portions, e.g., for directing signals in accordance with multiple signal delivery parameters, housed in a single housing (as shown in FIG. 1) or in multiple housings.
  • [0043]
    In some embodiments, the pulse generator 101 can obtain power to generate the therapy signals from an external power source 105. The external power source 105, which is arranged external to the patient, can transmit power to the implanted pulse generator 101 using electromagnetic induction (e.g., RF signals). For example, the external power source 105 can include an external coil 106 that communicates with a corresponding coil (not shown) within the implantable pulse generator 101. The external power source 105 can be portable for ease of use.
  • [0044]
    In another embodiment, the pulse generator 101 can obtain the power to generate therapy signals from an internal power source. For example, the implanted pulse generator 101 can include a non-rechargeable battery or a rechargeable battery to provide the power. When the internal power source includes a rechargeable battery, the external power source 105 can be used to recharge the battery. The external power source 105 in turn can be recharged from a suitable power source e.g., via a standard power plug 107.
  • [0045]
    In still further embodiments, an external programmer (not shown) can communicate with the implantable pulse generator 101 via electromagnetic induction. Accordingly, a practitioner can update the therapy instructions provided by the pulse generator 101. Optionally, the patient may also have control over at least some therapy functions, e.g., starting and/or stopping the pulse generator 101.
  • [0046]
    FIG. 2 illustrates another therapy system 200 in which the implantable pulse generator 101 is connected to percutaneous lead bodies 108 and 109, which are in turn connected to electrodes 110. The leads 108, 109 and electrodes 110 are shown in a bipolar configuration with two electrodes 110 carried by each lead 108, 109. In other embodiments, however, the leads 108, 109 can each contain more electrodes 110 (e.g., three, four, five, eight, or more) for applying therapy signals. In any of the foregoing embodiments, the electrodes (e.g., the electrode array 103 or the electrodes 110 of the percutaneous leads 108, 109) can be arranged adjacent different nerve fibers within the patient to enable the application of different types of therapy, as is discussed further below.
  • [0047]
    FIG. 3 is a cross-sectional illustration of a spinal region SR that includes the spinal cord SC and an adjacent vertebra VT (based generally on information from Crossman and Neary, “Neuroanatomy,” 1995 (publ. by Churchill Livingstone)), along with selected representative locations for representative leads 108 (shown as leads 108 a-108 d) in accordance with several embodiments of the disclosure. The spinal cord SC is situated between a ventrally located vertebral body WB and a dorsally located vertebral body DVB that includes a transverse process 198 and spinous process 197. Arrows V and D identify ventral and dorsal directions, respectively. In particular embodiments, the vertebra VT and leads can be at T10 or T11 (e.g., for axial low back pain or leg pain) and in other embodiments, the leads can be placed at other locations. The spinal cord SC itself is located within the dura mater DM, which also surrounds portions of the nerves exiting the spinal cord SC, including the dorsal roots DR, dorsal root ganglia G and ventral roots VR. The spinal cord SC is illustrated as having identifiable areas of afferent and efferent fibers including ascending pathway areas AP and descending pathway areas DP.
  • [0048]
    The leads are generally positioned to stimulate tactile fibers and to avoid stimulating fibers associated with nociceptive pain transmission. In a particular embodiment, a lead 108 a (e.g., a first lead) can be positioned centrally in a lateral direction (e.g., aligned with the spinal cord midline ML) to provide signals directly to the dorsal column DC of spinal cord SC. In other embodiments, the first lead can be located laterally from the midline ML. For example, single or paired leads can be positioned just off the spinal cord midline ML (as indicated by leads 108 b) to provide signals to the dorsal column DC. One or more other leads (e.g., second leads) can be positioned proximate to the dorsal root DR or dorsal root entry zone DREZ (e.g., 1-4 mm from the spinal cord midline ML, as indicated generally by lead 108 c), and/or proximate to the dorsal root ganglion G (as indicated by lead 108 d). Other suitable locations for the second lead include the “gutter,” also located laterally from the midline ML. In still further embodiments, the leads 108 may have other locations proximate to the spinal cord SC and/or proximate to other target neural populations e.g., laterally from the midline ML and medially from the dorsal root ganglion 194. For example, the leads can be located subdurally rather epidurally, as shown in dashed lines for midline lead 108 a and off-midline leads 108 b. The practitioner may select any of a variety of combinations of the foregoing locations, depending on the particular patient's needs and condition. In at least some embodiments, the practitioner can place two leads, each positioned to direct signals to a different target location (e.g., neural population) of the patient's spinal cord SC. In other embodiments, a single lead may have electrodes positioned at two or more target locations. In either case, individual electrodes can deliver signals with different characteristics to different neural populations to achieve a beneficial effect for the patient.
  • A. Therapy Options
  • [0049]
    In general, different types of therapy signals can be applied to the nerve fibers of a patient to different effect. For example, applying a low-frequency (LF) therapy signal to the nerve fibers of a patient can stimulate the nerve fibers to create an effect known in the art as “paresthesia,” which creates a sensation of numbness in the patient. This paresthesia effect can mask chronic pain, providing relief to the patient. Such an application of therapy signals is generally known as Spinal Cord Stimulation (SCS) therapy. In a particular embodiment of the present disclosure, the LF signal can have a frequency in the range of up to about 1,500 Hz, and a pulse width equal to or less than half of the period of the signal. In a particular embodiment, the LF signal can have a frequency in the range of from about 40 Hz to about 500 Hz.
  • [0050]
    Applying a high-frequency (HF) therapy signal to the nerves can produce a block or partial block on the nerves. Accordingly, as used herein, the term “block” refers generally to an at least partial block (e.g., a partial or complete block), and the term “blocking signal” refers generally to a signal that creates an at least partial block. In addition, while it is believed that the block inhibits or prevents the transmission of neural signals, a desired effect on the patient (e.g., pain reduction) is not necessarily limited to such a mechanism, and in at least some embodiments, pain reduction may be achieved by one or more other mechanisms. This block inhibits and/or prevents excitatory responses from reaching the brain of the patient. Typically, the HF therapy signal includes a biphasic signal. In a particular embodiment, the HF therapy signal is a biphasic (alternating current) signal having a 50% duty cycle and a frequency in the range of from about 2,500 Hz to about 100,000 Hz. In particular embodiments, the HF signal can have a frequency in the range of from about 2,500 Hz to about 20,000 Hz, and in further particular embodiments, about 3,000 Hz to about 10,000 Hz.
  • [0051]
    Representative examples of HF signal waveforms that can be applied to the dorsal column DC (FIG. 3) are shown in FIGS. 4 and 5. The signal waveforms shown in FIG. 4 include biphasic, charge balanced, square wave pulses. In the example shown, a first waveform 400 is applied to a first signal channel C1 and a second waveform 450 is applied to a second signal channel C2. In a particular embodiment, the waveform on the first signal channel C1 is interlaced with the waveform on the second signal channel C2 to minimize interaction between the signals 400, 450. This option is generally available when the HF signal is applied at a duty cycle of less than 50%, using one or more contacts that are shared between the first channel C1 and the second channel C2. When the HF signal has a 50% duty cycle, separate dedicated contacts can be used for each of the first and second channels C1, C2 to avoid interference between signals on the two channels. In still further embodiments, signal waveforms other than those shown in FIG. 4 can be used. For example, FIG. 5 illustrates biphasic, charge balanced, sinusoidal pulses 500, 550 which can be applied via the first and second signal channels C1, C2, respectively.
  • [0052]
    Detailed treatment processes for administering therapy signals for chronic pain management are described below. In certain embodiments, a physician or other practitioner can choose to combine two or more of the treatment processes described below for administering therapy for chronic pain management. The combination of the different types of therapy can provide pain relief on multiple fronts, providing extended coverage to the patient. For example, in one embodiment, multiple treatment processes can be applied to a patient simultaneously. In other embodiments, the therapies can be combined, but chronologically spaced, or offset, which can also have advantages. For example, as noted in further detail later, one therapy signal can be used to facilitate the initialization and/or the maintenance of another therapy signal.
  • [0053]
    1. Blocking at the Dorsal Column
  • [0054]
    A representative first treatment process for administering therapy for chronic pain management includes applying an HF blocking signal directly to the dorsal column DC of the patient. For example, FIG. 6 is a schematic depiction of a representative HF blocking signal 600 applied to the dorsal column DC. This HF blocking signal can be applied to the dorsal column DC in place of an LF stimulation signal to replace the pain relief provided by the paresthesia.
  • [0055]
    In general, the HF stimulation blocking signal 600 is applied to the dorsal column DC to establish a partial or total neuronal block at the dorsal column DC sufficient to block the chronic pain felt by the patient. The HF therapy signal can be applied to one or more select regions (e.g., vertebral levels) of the dorsal column DC to block transmission of pain signals from lower dermatomes. The HF blocking signal can inhibit or prevent the sensation of pain (e.g., to effect anesthesia) in the dermatomes corresponding to the selected regions.
  • [0056]
    2. Blocking at the Dorsal Root and/or the Dorsal Root Ganglion
  • [0057]
    In a representative second treatment process for administering therapy for chronic pain management, an HF blocking signal is applied to one or more dorsal roots DR and/or dorsal root ganglion(s) G of a patient, instead of directly to the dorsal column DC. FIG. 7 is a schematic depiction of an example HF blocking signal 700 applied to the dorsal root DR. Blocking at the dorsal root DR and/or the dorsal root ganglion G facilitates blocking sensation signals associated with one or more select regions of the body. In contrast, blocking at the dorsal column DC generally blocks only tactile and proprioceptive signals, generally at all dermatomes associated with sections of the dorsal column DC located below the blocking electrodes.
  • [0058]
    Arranging the electrodes (e.g., the electrodes carried by the array 103 shown in FIG. 1 or the electrodes 110 shown in FIG. 2) at the dorsal root DR and/or dorsal root ganglion G can enhance the range and effectiveness of the therapy signals. At such locations, the CSF fluid layer is not as thick as it is at the dorsal column DC, which can allow more current to flow to the spinal region. The CSF fluid layer is thicker closer to the dorsal column DC, which can shunt much of the current before the current reaches the dorsal column DC. By positioning the electrodes away from the dorsal column DC, it is expected that an electrical block of the nerve fibers may be established with less power.
  • [0059]
    In addition, sensory nerve responses typically proceed through the dorsal roots DR to the dorsal column DC, whereas motor nerve responses proceed through the ventral roots VR (see FIG. 3) to the spinal cord SC. Applying therapy signals to the dorsal root DR, therefore, can facilitate blocking of sensory responses (e.g., pain) without decreasing or eliminating the transmission of motor control impulses.
  • [0060]
    3. Blocking at Peripheral Nerves
  • [0061]
    In a third treatment process for administering therapy for chronic pain management, an HF blocking signal can be applied to the peripheral nerves of the patient (e.g., the nerves distal of the spinal cord SC). For example, an HF blocking signal can be applied to the somatic nerves of the patient. In another embodiment, the HF blocking signal can be applied to the autonomic nerves of the patient. Applying the HF block to the peripheral nerves can enable placement of the electrodes away from the spinal cord SC and the spinal fluid, and can therefore reduce the likelihood for interference with spinal function.
  • [0062]
    4. Combining Blocking with Stimulation Therapy
  • [0063]
    Other treatment processes for administering therapy for chronic pain management combine the application of an HF blocking signal with the process of applying an LF stimulating signal to the dorsal column DC of the patient to induce paresthesia. In general, the HF blocking signal can facilitate the inducement of paresthesia by alleviating patient discomfort resulting from the application of the LF stimulation signal.
  • [0064]
    The application of an LF stimulation signal to the dorsal column DC can induce paresthesia and/or induce patient discomfort, depending on the distance between the electrode(s) and the spinal cord (e.g., the thickness of the intermediate cerebral spinal fluid layer). As used herein, the term “discomfort” refers generally to an unpleasant, undesirable, uncomfortable and/or unwanted sensation or other response. The term includes, but is not limited to, pain. Typically, in conventional SCS treatment, patient discomfort results from the inadvertent application of the electric field produced by the electrode(s) to an adjacent dorsal root DR. In general, the greater the distance between the electrode and the spinal cord, the greater the likelihood that the electric field will interact with the dorsal root DR to stimulate pain sensations on the dorsal root DR, thus causing discomfort and/or pain as the signal amplitude is increased.
  • [0065]
    FIG. 8 schematically depicts the amplitude of an LF stimulation signal likely to induce paresthesia (represented by threshold curve TP) and the amplitude of the LF stimulation signal likely to induce patient discomfort (represented by threshold curve TD) as a function of spacing between the electrodes and the spinal cord. FIG. 8 is not intended as an exact plot of amplitude as a function of the spacing, but rather is intended to illustrate the general relationship amongst the paresthesia threshold TP, the patient discomfort threshold TD, and the spacing.
  • [0066]
    As shown in FIG. 8, when the electrodes are spaced relatively close to the spinal cord (e.g., when the spacing is less than about distance X), the electric field created by the electrode(s) induces paresthesia before causing discomfort. However, when the electrodes are spaced farther from the spinal cord (e.g., when the spacing is greater than about distance X), the LF stimulation signal can stimulate the dorsal root DR fibers, thereby potentially causing discomfort, before stimulating the dorsal column fibers at a level sufficient to induce paresthesia. The paresthesia threshold TP and the patient discomfort threshold TD cross at the electrode spacing distance X, which is approximately 2 mm in at least some embodiments, and can vary depending on factors that include signal delivery parameters. Further details regarding the relationship amongst electrode spacing, paresthesia, and pain can be found, e.g., in Effectiveness of Spinal Cord Stimulation in the Management of Chronic Pain: Analysis of Technical Drawbacks and Solutions by Jan Holsheimer (Neurosurgery, Vol. 40, No. 5, May 1997), the disclosure of which is hereby incorporated herein by reference in its entirety.
  • [0067]
    Some combination treatment processes in accordance with embodiments of the disclosure for administering therapy for chronic pain management use an HF blocking signal to inhibit the discomfort sensation produced when the LF signal amplitude reaches the discomfort threshold TD, thereby enabling the amplitude of the LF signal to be increased further to the paresthesia threshold TP. This in turn can allow the LF signal to be effective, even if it is provided by an electrode that would otherwise be too far away from the target nerve region (e.g., the dorsal column) to produce paresthesia without also producing discomfort. Other combination treatment processes augment the pain relief provided by paresthesia with the pain relief provided by blocking different sections of the spinal region, as will be discussed later.
  • [0068]
    a. Blocking at Dorsal Root
  • [0069]
    A representative fourth treatment process for administering therapy for chronic pain management applies an HF blocking signal to the dorsal root DR (and/or dorsal root ganglion G) while applying the LF stimulating signal at the dorsal column DC. As used herein, the term “dorsal root” can include the dorsal root itself, the dorsal root entry region, and the conus. FIG. 9 is a schematic illustration of an HF blocking signal 900 applied to the dorsal root DR of a patient, and an LF stimulating signal 950 applied to the dorsal column DC. The HF signal can establish a block on the dorsal root DR that inhibits the transmission to the brain of pain sensations induced by the electric field of the LF stimulation signal.
  • [0070]
    In some embodiments, the HF blocking signal 900 is applied to the dorsal root DR prior to application of the LF stimulating signal 950 to the dorsal column DC. In other embodiments, however, the HF blocking signal 900 can be applied at generally the same time as or after the LF stimulating signal 950 is applied to the dorsal column DC. In one embodiment, the LF stimulation signal 950 can be initiated with a low-level amplitude that is subsequently ramped up to a suitable operating amplitude.
  • [0071]
    In other embodiments, the HF blocking signal applied to the dorsal root DR augments the pain relief provided by the paresthesia. For example, blocking the dorsal root DR is expected to block peripheral pain (e.g., any peripheral pain) from being transmitted through the dorsal root DR. This can include not only discomfort caused by the LF signal, but also the pain that the LF signal is expected to address.
  • [0072]
    b. Blocking at Dorsal Column
  • [0073]
    A representative fifth treatment process for administering therapy for chronic pain management applies an HF blocking signal at a first section of the dorsal column DC while applying the LF stimulating signal at a second section the dorsal column DC. The LF stimulating signal is expected to induce a sensation of paresthesia in dermatomes (e.g., all dermatomes) associated with the second section of the dorsal column DC and lower sections (e.g., all lower sections). The HF blocking signal is expected to block excitatory responses produced at the first section and lower sections from reaching the brain.
  • [0074]
    In some embodiments, the HF blocking signal is applied to the dorsal column DC prior to application of the LF stimulating signal to the dorsal column DC. In other embodiments, however, the HF blocking signal can be applied at substantially the same time as or after the LF stimulating signal is applied. In one embodiment, the LF stimulation signal can be initiated with a low-level amplitude that is subsequently ramped up to a suitable operating amplitude.
  • [0075]
    In other embodiments, the HF blocking signal applied to the dorsal column DC augments the pain relief provided by the paresthesia. For example, the LF stimulating signal can boost nerve responses that inhibit the sensation of pain and the HF blocking signal can inhibit nerve responses that transmit pain signals to the brain.
  • [0076]
    In general, the HF signal can be applied to the dorsal column DC above (superior) or below (inferior) the site at which the LF signal is applied. Signals applied to the dorsal column DC will tend to induce action potentials in both directions along the target sensory signal route, e.g., toward the brain (orthodromic) and away from the brain (antidromic). If the orthodromic LF signal creates a pleasant (or at least non-objectionable) sensation, such as tingling, that masks the target pain, then there may be no need for an HF signal applied to the dorsal column DC. However, if the LF signal creates an unpleasant sensation (an orthodromic signal), and the corresponding antidromic signal acts to mitigate the target pain, then an HF signal may be applied superior to the LF stimulation site to suppress the unpleasant sensation caused by the orthodromic signal, while having no effect on the beneficial antidromic signal. Accordingly, the patient can be outfitted with a device that includes an LF signal generator coupled to electrical contacts at the dorsal column, and an HF signal generator coupled to electrical contacts located superiorly on the dorsal column DC. In particular embodiments, the HF signal generator is activated if (a) the paresthesia created by the LF signal is objectionable to the patient, and (b) the antidromic action potentials created by the LF signal reduce the target pain.
  • [0077]
    In another embodiment, the HF signals can be applied to the dorsal column DC at a location inferior to where the LF signals are applied. In this case, it is assumed that the antidromic signals produced by the LF signals do not contribute (or do not contribute significantly) to reducing the target pain. Accordingly, applying HF signals at an inferior location, which is expected to block such antidromic signals, is not expected to impact the effectiveness of the LF signals, e.g., the orthodromic paresthesia effect. It is further assumed, based on recent evidence, that dorsal column DC fibers transmit pain, in contrast to more traditional models which posit that pain travels through the spinothalamic tract. Based on this assumption, blocking orthodromic pain signals passing along the dorsal column is expected to reduce the target pain.
  • B. Treatment Parameters
  • [0078]
    In general, the therapy systems 100, 200 (FIGS. 1 and 2) can be utilized to provide chronic pain management to patients using one of the above described therapy options, or one or more combinations thereof. The following treatment parameters are representative of treatment parameters in accordance with particular embodiments.
  • [0079]
    1. Signal Parameters
  • [0080]
    In general, HF blocking signals can have a frequency ranging between about 2,500 Hz and about 100,000 Hz. In a particular embodiment, the HF blocking signal has a frequency ranging between about 2,500 Hz and about 20,000 Hz and in another particular embodiment, between about 3,000 Hz and about 10,000 Hz. In other particular embodiments, the HF signal has a frequency of greater than 10,000 Hz. Frequencies above 10,000 Hz may result in shorter transition times, e.g., shorter times required to establish a block. The current of the HF blocking signals generally can range from about 2 mA to about 20 mA. In a particular embodiment, the current of a representative HF blocking signal is about 5-10 mA.
  • [0081]
    2. Modulating Signal Amplitude After Initialization
  • [0082]
    After an HF blocking signal has been initialized, the amplitude of the blocking signal can be reduced from a first operating level to a second, lower operating level without affecting the sensory experience of the patient. For example, in particular embodiments, the amplitude of the HF blocking signal can be reduced by about 10-30% after initialization without affecting the established block. Such a result can advantageously decrease the amount of power required to operate the therapy system 100, 200 (FIGS. 1 and 2). For example, decreasing the operating power can increase the battery life of the pulse generator 101 or otherwise decrease the drain on the power source.
  • [0083]
    3. Modulation of On/Off Time
  • [0084]
    In certain embodiments, therapy can be applied in a discontinuous fashion so as to include periods when the therapy is applied, and periods when the therapy is terminated according to a duty cycle. In different embodiments, therapy application periods can range from a few seconds to a few hours. In other embodiments, the duty cycle of a therapy signal can extend over a few milliseconds.
  • C. Initializing Blocking Signals
  • [0085]
    When HF blocking signals are initially applied to nerve fibers, the patient can experience an onset response before the block takes effect. An onset response is induced by a brief activation of the nerve fibers resulting in sudden pain and/or involuntary muscle contractions. Such an onset response can occur regardless of whether the therapy signals are applied to the dorsal column DC, the dorsal root DR, the dorsal root ganglions G, or to the peripheral nerves of the patient.
  • [0086]
    In order to alleviate these symptoms, various initialization procedures can be used as described below. For example, the nerve activation caused by initializing the blocking signal can be mitigated by adjusting the signal parameters (e.g., amplitude and/or frequency) of the blocking signal. Alternatively, patient discomfort caused by the onset response can be masked by applying additional pain management therapy.
  • [0087]
    1. Mitigating an Onset Response
  • [0088]
    As the term is used herein, mitigation of an onset response refers generally to a decrease in the otherwise resulting activation of the nerve to which the blocking signal is being applied.
  • [0089]
    a. Amplitude Ramp-Up
  • [0090]
    A first initialization procedure for mitigating patient onset response includes gradually ramping up the amplitude of the blocking signal being applied to the nerve. As the term is used herein, the amplitude of the blocking signal can refer to the current amplitude and/or the voltage amplitude of the signal since a direct relationship exists between the current and the voltage of the blocking signal.
  • [0091]
    By starting the signal at a lower amplitude, fewer nerve fibers are affected and stimulated initially. As the amplitude is increased, additional nerve fibers are stimulated as the block is established at the previous nerve fibers. The total number of nerve fibers activated at any one time, therefore, is decreased when compared with an un-ramped initialization. Patient discomfort that may be caused by the stimulated fibers is likewise expected to be mitigated.
  • [0092]
    For example, in FIG. 10, the amplitude and/or frequency of representative blocking signal 1000 is gradually increased to an operating amplitude OA over a finite period of time. In one embodiment, the amplitude of the waveform 1000 is increased over a period of a few seconds. In other embodiments, however, the amplitude and/or frequency can be increased over a greater or lesser period of a time (e.g., a few minutes or a few milliseconds). In still further embodiments, the amplitude and/or frequency can be decreased over time, as is discussed further below with reference to FIGS. 11A-11C.
  • [0093]
    b. Amplitude and Frequency Modulation
  • [0094]
    Referring to FIGS. 11A-11C, a second initialization procedure for reducing the onset response to treatment can include at least two phases, one in which the applied frequency and/or amplitude are above general operating levels, and one in which the frequency and/or amplitude are reduced to operating levels. These phases, as well as additional (and in some cases, optional) phases are described below.
  • [0095]
    In some embodiments, the second initialization procedure can include an optional onset phase P0 during which the frequency of the blocking signal is maintained at a constant level F1 (see FIG. 11A) and the amplitude of the blocking signal is ramped up from a low amplitude A1 to a high amplitude A2 (see FIG. 11B).
  • [0096]
    In a first phase P1, a blocking signal having a frequency F1 and amplitude A2 greater than the general operating frequency FO1 and operating amplitude AO1 is applied to a nerve. For example, a blocking signal having a frequency in the range of about 2,500 Hz to above 20 KHz and an amplitude up to about 20 mA can be applied during the first phase P1.
  • [0097]
    In some embodiments, the application of the blocking signal having a very high frequency F1 and a high amplitude A2 rapidly results in a block on the nerve. In other embodiments, however, the second initialization procedure can include an optional transition phase P2 during which a block is established (i.e., during which the signal increases in strength above the threshold T1). Even when the transition phase P2 is utilized, however, the blocking signal establishes a block on the nerve more rapidly than would a signal that simply has the operating frequency and operating amplitude.
  • [0098]
    During the transition phase P2, the frequency of the blocking signal is decreased from the very high frequency F1 to a frequency F2 (see FIG. 11A). Frequency F2 is lower than frequency F1, but still significantly higher than the operating frequency FO. Decreasing the frequency increases the charge per phase and hence the strength of the blocking signal (see FIG. 11C). The frequency is lowered until the signal strength crosses the blocking threshold T1. In one embodiment, the amplitude may be further increased as well during the transition phase P2.
  • [0099]
    In a subsequent phase P3, the frequency and amplitude of the blocking signal can be reduced from a level at which the block is established to first operating levels (e.g., FO1, AO1 shown in FIG. 11B). In one embodiment, a block is established when the charge per phase of the blocking signal passes above a blocking threshold T1 (see FIG. 11C). Decreasing the amplitude of the blocking signal lessens the drain on the power source. Decreasing the frequency increases the charge per phase (e.g., the stimulation applied to the nerve fibers) to compensate for the reduction in amplitude. In one embodiment, a practitioner begins ramping down the frequency and the amplitude concurrently. In other embodiments, however, the amplitude and frequency can be ramped down at different times.
  • [0100]
    In some embodiments, an optional phase P4 includes decreasing the amplitude of the signal from the first operating level AO1 to a different operating level AO2 after the block is established (see FIG. 11B). Decreasing the amplitude lowers the charge per phase (see FIG. 11C). The block can be maintained, even if the charge per phase drops below the first threshold T1, as long as the charge per phase does not drop below a second threshold T2 (see FIG. 11C). Typically, threshold T2 is 10-30% less than the threshold T1.
  • [0101]
    FIG. 12 is a schematic depiction of an example blocking signal 1200 initially having a high frequency F1 (e.g., about 30-50 KHz) and a high amplitude A2 (e.g., about 15-20 mA). In the example shown, the blocking signal 1200 is a biphasic, charge balanced, square waveform. In other embodiments, however, the blocking signal 1200 can include any desired waveform. When the block on the nerve is established, the amplitude of the blocking signal 1200 is ramped down to an appropriate operating level AO (e.g., about 5-10 mA). As further shown in FIG. 12, the frequency of the blocking signal 1200 also can be decreased to an appropriate operating level FO (e.g. about 3-10 KHz).
  • [0102]
    FIG. 13 shows the blocking signal 1200 having an initial ramp-up period shown at 1200 a, during which the signal amplitude is increased to a maximum amplitude MA. Ramping up the amplitude of the signal can allow the signal to be initiated safely with reduced or non-existent patient discomfort. In other embodiments, however, the onset phase P0 can be skipped and the very high amplitude A2 of the blocking signal can be applied from the beginning.
  • [0103]
    2. Masking Onset Response
  • [0104]
    As the term is used herein, masking of an onset response refers generally to a decrease in the discomfort of the patient otherwise resulting from an onset response, without affecting activation of the nerve to which the blocking signal is being applied.
  • [0105]
    a. Inducing Paresthesia
  • [0106]
    Referring to FIG. 14, paresthesia induced by an LF stimulating signal applied to the dorsal column DC can mitigate the onset response of an HF blocking signal applied to the dorsal root DR. The low-level paresthesia, while not strong enough to control the chronic pain of the patient, can alleviate some or all of the discomfort experienced by the patient as a result of the initialization of the HF blocking signal. Examples of the relative timing for the therapy signals are shown in FIG. 14.
  • [0107]
    As shown in FIG. 14, an LF stimulating signal 1450 having a low amplitude and a low frequency (e.g., in the range of about 40 Hz to about 250 Hz) is applied to the dorsal column DC of a patient to induce paresthesia. Next, an HF blocking signal 1400 having a high frequency (e.g., ranging from about 2,500 Hz to about 100,000 Hz, and in a particular embodiment, from about 2,500 Hz to about 20,000 Hz, and in a further particular embodiment, about 2,500 Hz to about 10,000 Hz) is applied to the dorsal root DR of the patient. The paresthesia induced by stimulating the dorsal column DC can enhance patient comfort while the partial or complete HF block is established at the dorsal root DR. In a representative example, an LF signal is applied to the dorsal column DC for a period of several seconds before applying the HF signal, at least up to an amplitude below that which causes discomfort and/or pain. In particular embodiments (e.g., in cases for which the HF blocking signal by itself has a sufficient therapeutic effect), the LF signal can be halted once the HF signal is established and the period for experiencing an onset response has passed. In a representative embodiment, this time period can be from about 5 seconds to about 5 minutes. The LF signal can then be re-established for a short period the next time an HF signal is initiated to again reduce or eliminate the onset response. In this manner, the onset response can be controlled without requiring a continuous (and therefore power consuming) LF signal. This arrangement can be used when the LF signal is applied at a location superior to the HF signal location, e.g., when both the LF and HF signals are applied to the dorsal column DC, or when the LF signal is applied to the dorsal column DC above a dorsal root DR location at which the HF signal is applied.
  • [0108]
    b. Pharmacological Anesthetic
  • [0109]
    One or more pharmaceutical drugs affecting the pain neural transmission synapse or neuromuscular junction also can be given to the patient prior to initiating a therapy signal, such as an HF blocking signal. For example, bupivacaine and/or other suitable local anesthetics may be used in this regard, when injected epidurally. The various classes of analgesics used for epidural and spinal block include local anesthetics, opioids, adrenergic agonists, and cholinergic agonists. Local anesthetics inhibit neural conduction by reversibly blocking conductance in axonal sodium channels. Opioids exert their effect by reversibly binding to opioid receptors in the dorsal horn of the spinal cord. Alpha-2 adrenergic agents interact with alpha-2 adrenergic receptors in the spinal cord, and cholinergic agonists produce analgesia by increasing the concentration of acetylcholine proximate to muscarinic and nicotinic receptors in the superficial layers of the dorsal horn of the spinal cord. The pharmacological agent can be delivered via the same device that supplies the electrical signals, or the agent can be delivered via a separate device. In a particular embodiment, PLGA or another suitable polymer can be used to exude the agent.
  • D. Electrode Configurations
  • [0110]
    FIGS. 15-18 illustrate different design variations that include an electrode array having four electrodes. In other embodiments, arrays can include a greater or lesser number of electrodes arranged in the same or other patterns. In a particular embodiment, an array can contain two electrodes. In another embodiment, an array can contain three electrodes. In yet another embodiment, an array can contain up to sixteen or more electrodes. Increasing the number of electrodes increases the number of channel vectors which can be utilized during therapy, thereby broadening the types of therapy applied and/or the regions over which the therapy is applied.
  • [0111]
    FIG. 15 illustrates an example electrode array 119 including four electrodes 115, 116, 117, 118 implanted at the spinal cord SC. In the embodiment shown in FIG. 15, a first therapy signal (e.g., for affecting paresthesia at the dorsal column DC) is applied via a first output channel C1 (shown schematically) of the array 119 that extends along the dorsal column DC and can include a first pair of electrodes 116, 117. A second therapy signal (e.g., for blocking pain in the dorsal root DR) is transmitted via a second output channel C2 (shown schematically) of the array 119 that extends at an angle (e.g., 10°, 30°, 60°, 90°, 120°, etc.) to the first output channel C1 and can include a second pair of electrodes 115, 116.
  • [0112]
    In such a configuration, the vector of the electrical stimulation applied via the first channel C1 between electrode 116 and electrode 117 is angled relative to the vector of the electrical stimulation applied through the second channel C2 between electrode 116 and electrode 115. By arranging the electrodes to provide angled (e.g., orthogonal) signal channels C1, C2, electric field interaction between the channels C1, C2 can be reduced or minimized. Furthermore, the first channel C1 can be oriented to align with the dorsal column DC and the second channel C2 can be oriented to align with the dorsal root DR. For example, the second channel C2 can be arranged generally orthogonal adjacent the thoracic region of the spine, and more acutely angled closer to the lumbar region.
  • [0113]
    The remaining electrode 118 can be used to create other channels for applying therapy signals. For example, if the dorsal root crosses the electrode array 119 above the second pair of electrodes 115, 116, then the second therapy signal can be applied along a third channel (not shown) between electrodes 117, 118 to block the dorsal root DR. In other embodiments, the remaining electrode 118 can provide other stimulation vectors for the dorsal column DC to further optimize the therapy.
  • [0114]
    The foregoing arrangement, in which one of the first electrodes (e.g., first electrode 116) forms part of both the first channel C1 and the second channel C2 can be suitable when the signals applied to both channels C1, C2 are interlaced. For example, this arrangement can be suitable when an HF signal applied to the second channel C2 has a duty cycle of less than 50%, and an LF signal applied to the first channel C1 is interlaced with the HF signal. In another arrangement (shown in dashed lines in FIG. 15), an additional first electrode 116 a is used in combination with the electrode 117 for the first channel C1, and electrodes 115, 116 form a separate second channel C2. This arrangement can be used when the duty cycle applied to one or both channels C1, C2 is 50%. Though not shown for purposes of clarity, a similar arrangement can be applied to the embodiments shown in other Figures as well, e.g., FIGS. 16 and 18.
  • [0115]
    a. Lateral Spacing
  • [0116]
    FIG. 16 shows an electrode array 120, which is a variant of the electrode array 119 shown in FIG. 15. The electrode array 120 includes an electrode 123 that is laterally offset from the corresponding electrode 115 shown in FIG. 14 and accordingly forms a second output channel C2 a having an increased length. The increased length of the channel C2 a produces an electric field having a wider coverage. In specific patient anatomies, an increased field can be advantageous, for example, when it is desirable to block an increased number of fibers. In general, the larger the electric field, the greater number of nerve fibers affected by the therapy signal. When applied along the dorsal column DC, a large electric field penetrates deeper and more laterally into the dorsal column DC, thereby inhibiting pain over a large region of the body (e.g., by covering multiple dermatomes).
  • [0117]
    However, as noted above, it is not always desirable to affect large regions of nerve fiber. For example, a larger electric field applied to the dorsal column DC may be more likely to “leak” to adjacent fibers on the dorsal root DR or ventral root. In addition, a larger electric field can stimulate or block fibers carrying motor control impulses (e.g., ventral roots). Large electric fields can be more likely to affect these motor nerve fibers and cause undesirable side effects to the treatment. Accordingly, in at least some such instances, the array 119 shown in FIG. 15 may be more appropriate.
  • [0118]
    b. Axial Spacing
  • [0119]
    Electrodes within an electrode array also can be axially spaced to increase the penetration along the dorsal column DC. For example, in an arrangement shown in FIG. 17, an electrode array 121 can include an electrode 124 axially aligned with electrodes 116, 117, but arranged in an axially inferior position relative to the electrode 116.
  • [0120]
    In some embodiments, channels can be formed between non-adjacent electrodes to increase the length of the channels. For example, in the embodiment shown in FIG. 17, the electrode 124 can form a first channel C1 a with the electrode 117. In other embodiments, however, channel length is increased by increasing the spacing between adjacent electrodes.
  • [0121]
    c. Non-Orthogonal Orientation
  • [0122]
    In certain embodiments, electrode arrays can be configured to provide vectors for electrical stimulation that reflect the anatomy of the patient. For example, an electrode array 122 shown in FIG. 18 includes electrodes 115, 116, 117 that are generally similar to the corresponding electrodes discussed above with reference to the array 119. In addition, the electrode array 122 includes an electrode 125 spaced axially from electrode 115. In the example shown, the electrode 125 is spaced at an axially inferior position relative to electrode 115. Electrode 125 can be included in place of electrode 118 of array 119.
  • [0123]
    Electrode array 122 can advantageously provide channel vectors (e.g., channel C2 b) oriented in directions generally followed by dorsal roots DR leaving the dorsal column DC at the intervertebral foramen of the spinal cord SC. Proximal the brain, the dorsal root DR branches from the dorsal column DC at a generally orthogonal orientation relative to the dorsal column DC. Distal of the brain, however, the dorsal roots DR branch from the dorsal column DC at increasingly downward angles. Accordingly, an array of the type shown in FIG. 18 may be particularly suitable for applications distal of the brain.
  • [0124]
    3. Percutaneous Lead Configurations
  • [0125]
    Various details of array electrode configurations are described above. It will be appreciated that many of the same electrode configurations can be achieved by the use of bipolar or multi-polar, percutaneous leads as described in connection with FIGS. 19A-21. Typically, percutaneous leads require less invasive surgery and, therefore, are more convenient to implant than electrode arrays.
  • [0126]
    a. Bipolar Leads
  • [0127]
    A lead configuration 140, shown schematically in FIG. 19A, includes a first percutaneous lead 126 that is implanted within the patient together with a second percutaneous lead 130. The first percutaneous lead 126 has first and second electrodes 127, 129, respectively, and the second percutaneous lead 130 has first and second electrodes 131, 133, respectively. The electrodes 127, 129, 131, 133 are generally aligned along the spinal cord SC. Typically, the electrodes 127, 129 of the first lead 126 are aligned parallel, but laterally displaced from the electrodes 131, 133 of the second lead 130.
  • [0128]
    Therapy signals can be generated using one or both leads 126, 130. To apply a therapy signal to the dorsal column DC, the therapy signal is typically generated by electrodes arranged along a single lead (e.g., the first lead 126). To apply a therapy signal to the dorsal root DR, the therapy signal is typically generated by electrodes on two or more different leads (e.g., a first electrode 129 on the first lead 126, and a second electrode 133 on the second lead 130). In the example shown, an LF stimulation signal can be applied to the dorsal column DC via the first lead 126 and an HF blocking signal can be applied to the dorsal root DR via electrodes 129, 133 on the first and second leads 126, 130, respectively.
  • [0129]
    In other embodiments, other types of therapy signals can be applied via the first and second leads 126, 130. For example, an HF blocking signal can be applied to the dorsal column DC via the electrodes 131, 133 of the second lead 130.
  • [0130]
    FIG. 19B illustrates another embodiment in which a second lead 130 a is positioned along the dorsal root DR and a first lead 126 a is positioned along the dorsal column DC (see FIG. 19B). In one aspect of this embodiment, an up-regulating (e.g., paresthesia-inducing) signal can be applied to the first lead 126 a at the dorsal column DC and a down-regulating (e.g., blocking) signal can be applied to the second lead 130 a at the dorsal root DR.
  • [0131]
    FIG. 19C illustrates the inferior portion of the spine, including the lower lumbar and sacral vertebrae, and associated nerve roots. Signals (e.g., HF signals) can be applied to these roots alone or in conjunction with signals applied superiorly to the dorsal column. In particular arrangements, leads or pairs of leads can be positioned between adjacent roots to provide signals to a number of roots that is greater than the number of leads. For example, a first pair of leads 152 a, 154 b, each having electrodes or electrode contacts 160, can be positioned along opposite sides of the S3 root to provide signals to at least the S2, S3 and S4 roots. In another representative example, a second pair of leads 152 b, 154 b can be placed alongside the L5 root to provide signals to the L5 root, the S1 root and optionally the L4 root. In other embodiments, leads having similar (or other) structures can be placed along other roots. An advantage of the foregoing arrangement is that a reduced number of leads can be used to apply signals to a greater number of roots.
  • [0132]
    b. Multi-Channel Lead Arrangement
  • [0133]
    FIGS. 20 and 21 illustrate a multi-channel, percutaneous lead arrangement 150 having first and second leads 152, 154 configured to deliver multiple therapy signals to a patient. FIG. 20 illustrates how the lead arrangement 150 can be used generally to apply therapy signals to the dorsal column DC. FIG. 21 illustrates how the lead arrangement 150 can be used generally to apply therapy signals to the dorsal root DR. In different embodiments, the leads 152, 154 can cooperate to provide multiple types of therapy signals to the dorsal column DC and/or dorsal root DR of a patient.
  • [0134]
    Each lead 152, 154 of the lead arrangement 150 includes a first arrangement 155 of electrodes, a second arrangement 157 of electrodes, and a third arrangement 159 of electrodes. In the example shown, the first and third arrangements 155, 159 include bipolar electrodes. The second arrangement 157 includes a tripolar electrode arrangement (e.g., a central cathode with anodes on either side). In such an embodiment, current can be controlled independently to adjust therapy for variations in electrode-to-nerve positioning. In other embodiments, however, the leads 152, 154 can include other arrangements of electrodes. In the example shown, each lead 152, 154 of the lead arrangement 150 includes seven electrodes. In other embodiments, however, a lead can include one, two, three, four, five, or more electrodes.
  • [0135]
    In general, the first arrangement 155 of electrodes on one or both leads 152, 154 can apply an LF stimulation signal to the dorsal column DC to induce a sensation of paresthesia. Typically, the electric field of the stimulating signal can be generated by electrodes on a single lead so that the electric field is oriented along the length of the dorsal column DC. For example, in FIG. 20, the electrodes of the first arrangement 155 of the first lead 152 create an electric field at the dorsal column DC to induce a sensation of paresthesia.
  • [0136]
    In one embodiment, the electrodes of the second arrangement 157 of one of the leads 152, 154 can generate an electric field of an HF blocking signal at the dorsal column DC to establish a block on the dorsal column DC. For example, the electrodes of the second arrangement 157 can form a tripolar configuration to produce an HF blocking signal as shown in FIG. 20. In other configurations, the HF blocking signal can be generated using a lesser or greater number of electrodes of the second arrangement 157.
  • [0137]
    In another embodiment, the HF blocking signal can be applied to a dorsal root DR along at least some of the electrodes of the second arrangement 157 on both leads 152, 154. For example, in FIG. 21, the middle electrodes of the second arrangement 157 on both leads 152, 154 cooperate to form an electric field. This electric field is oriented generally orthogonal to the electric field form from the tripolar electrode arrangement of FIG. 20.
  • [0138]
    In other embodiments, additional electrodes from the second arrangement 157 on one of both leads 152, 154 can cooperate to form the electric field. For example, FIG. 21 also shows a therapy signal channel between a first electrode 157 a and a second electrode 157 b. The therapy channel is angled with respect to the leads 152, 154.
  • [0139]
    Such an angle may facilitate applying the therapy signal along the length of a dorsal root DR as the root branches from the dorsal column DC.
  • [0140]
    In the above paragraphs, a number of therapy combinations have been described which include dorsal column low frequency stimulation and/or high frequency blocking, dorsal root high frequency blocking, and peripheral nerve high frequency blocking. Procedures to avoid patient discomfort in the onset and subsequent therapy phases also have been discussed. In other embodiments, therapy can be performed in accordance with other permutations and combinations of the aforementioned parameters, time variations, and therapeutic phases.
  • [0141]
    To aid in understanding the above described treatment options, the following example applications are provided. FIG. 22 illustrates a first treatment signal 2610 being applied to nerves of a dorsal column DC of a patient. The first treatment signal 2610 is an LF signal configured to up-regulate the nerves of the dorsal column DC to induce a sensation of paresthesia, and can be provided by a first portion of the pulse generator 101 described above with reference to FIG. 1.
  • [0142]
    A second treatment signal 2620 is applied to a dorsal root DR of the patient subsequent to the initialization of the first treatment signal 2610. The second treatment signal 2620 is an HF signal configured to down-regulate the nerves of the dorsal root DR to establish a block on the nerves, and can be provided by a second portion of the pulse generator 101 described above with reference to FIG. 1. The paresthesia induced by the first treatment signal 2610 at least partially masks the onset response experienced by the patient when the second treatment signal 2620 is initiated.
  • [0143]
    As shown, a third treatment signal 2630 is applied to the dorsal column DC after the second treatment signal 2620 is initiated. In a particular embodiment, the third treatment signal 2630 is applied to the dorsal column DC after the second treatment signal 2620 establishes a block on the dorsal root DR. The third treatment signal 2630 is configured to establish a block on the dorsal column DC.
  • [0144]
    In another representative example, a practitioner can implant multiple electrodes at the patient's spinal region, with at least one of the electrodes positioned to provide spinal cord stimulation, and at least one of the electrodes positioned to apply signals to the dorsal root or the dorsal root ganglion. The practitioner can then apply an LF signal to the first electrode to induce paresthesia and address pain suffered by the patient. In at least some cases, the paresthesia may be sufficient to address the patient's pain symptoms, and accordingly, an HF signal need not be applied to the second electrode. In other instances, however, an initial LF signal applied to the first electrode may not adequately address the patient's pain. In such instances, the amplitude of the signal supplied to the first electrode may be increased to produce paresthesia. The increase may be required because the position of the first electrode is not optimal, and/or because of patient-specific physiological effects. In any of these embodiments, increasing the amplitude of the signal applied to the first electrode may, at the same time it causes paresthesia, separately cause patient discomfort. Accordingly, the practitioner can apply HF signals to the second electrode to block the patient discomfort, without the need for repositioning the first electrode. This arrangement can accordingly reduce the invasiveness of the implantation procedure.
  • [0145]
    In another example, the patient may suffer from lower back pain. The lower back pain may be transmitted along afferent nerve fibers that enter the spinal column channel at the L5 vertebrae, which is below the end of the spinal cord. Accordingly, the practitioner may apply LF spinal cord stimulation at a higher spinal elevation, for example, at the T10 vertebrae. In at least some instances, the paresthesia resulting from such LF signals may reduce pain somewhat, but not completely. Accordingly, the practitioner may additionally apply HF signals at the L5 location to block lower back pain sensations. In this instance, the HF signal is applied at a different spinal elevation than the low frequency signal.
  • [0146]
    In still another example, the patient may suffer from pain transmitted along several neural pathways that enter the spinal column at L1 (e.g., at the conus). The practitioner may apply HF signals at the conus, in combination with LF signals at a higher spinal elevation (e.g., T8, T9 or T10). This is unlike several existing stimulation techniques, which deliberately avoid the conus as an implantation/stimulation site.
  • [0147]
    From the foregoing, it will be appreciated that specific embodiments of the disclosure have been described herein for purposes of illustration, but that various modifications may be made without deviating from the disclosure. For example, the LF signals may be provided on a generally continuous basis in some embodiments, and may be turned off and on automatically in other embodiments, or in response to a patient request in still further embodiments. In some embodiments, directions and/or instructions were described in the context of a pulse generator, and in other embodiments, such directions and/or instructions may be handled by other controller components. Certain aspects of the disclosure described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, while HF and LF signals were discussed in the context of lower back pain and applied to different spinal elevations, in other embodiments, such signals may be applied at different spinal elevations to address other patient pain symptoms. Further, while advantages associated with certain embodiments have been described in the context of those embodiments, other embodiments may also exhibit such advantages. Not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure. Accordingly, the disclosure can include other embodiments not shown or described above.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3817254 *8 May 197218 Jun 1974Medtronic IncTranscutaneous stimulator and stimulation method
US4023574 *20 Oct 197517 May 1977Hans NemecElectrostimulation method and apparatus
US4155366 *16 May 197722 May 1979Ultra-Aids, Inc.Method of percutaneous pain alleviation
US4649935 *21 May 198417 Mar 1987Symtonic SaMethod of treating neurovegetative disorders and apparatus therefor
US4841973 *21 Sep 198727 Jun 1989Stecker Harold DElectrical stimulators
US5002053 *21 Apr 198926 Mar 1991University Of ArkansasMethod of and device for inducing locomotion by electrical stimulation of the spinal cord
US5514175 *9 Nov 19947 May 1996Cerebral Stimulation, Inc.Auricular electrical stimulator
US5716377 *25 Apr 199610 Feb 1998Medtronic, Inc.Method of treating movement disorders by brain stimulation
US5776170 *4 Feb 19947 Jul 1998Macdonald; Alexander John RanaldElectrotherapeutic apparatus
US6002964 *15 Jul 199814 Dec 1999Feler; Claudio A.Epidural nerve root stimulation
US6014588 *7 Apr 199811 Jan 2000Fitz; William R.Facet joint pain relief method and apparatus
US6027456 *10 Jul 199822 Feb 2000Advanced Neuromodulation Systems, Inc.Apparatus and method for positioning spinal cord stimulation leads
US6176242 *30 Apr 199923 Jan 2001Medtronic IncMethod of treating manic depression by brain infusion
US6238423 *30 Sep 199929 May 2001Medtronic, Inc.Apparatus and method for treating chronic constipation
US6246912 *19 Jul 199912 Jun 2001Sherwood Services AgModulated high frequency tissue modification
US6341236 *30 Apr 199922 Jan 2002Ivan OsorioVagal nerve stimulation techniques for treatment of epileptic seizures
US6356786 *20 Jan 200012 Mar 2002Electrocore Techniques, LlcMethod of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain
US6405079 *22 Sep 200011 Jun 2002Mehdi M. AnsariniaStimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions
US6505078 *10 Mar 20007 Jan 2003Medtronic, Inc.Technique for adjusting the locus of excitation of electrically excitable tissue
US6510347 *19 Apr 200121 Jan 2003William N. BorkanSpinal cord stimulation leads
US6516227 *26 Jul 20004 Feb 2003Advanced Bionics CorporationRechargeable spinal cord stimulator system
US6584358 *8 Jan 200124 Jun 2003Biowave CorporationElectro therapy method and apparatus
US6721603 *25 Jan 200213 Apr 2004Cyberonics, Inc.Nerve stimulation as a treatment for pain
US6871090 *10 Oct 200122 Mar 2005Advanced Bionics CorporationSwitching regulator for implantable spinal cord stimulation
US6885888 *23 Oct 200126 Apr 2005The Cleveland Clinic FoundationElectrical stimulation of the sympathetic nerve chain
US6907295 *24 Jul 200214 Jun 2005Biocontrol Medical Ltd.Electrode assembly for nerve control
US6990376 *6 Dec 200224 Jan 2006The Regents Of The University Of CaliforniaMethods and systems for selective control of bladder function
US7024246 *26 Apr 20024 Apr 2006Medtronic, IncAutomatic waveform output adjustment for an implantable medical device
US7047079 *25 Jul 200316 May 2006Advanced Neuromodulation Systems, Inc.Method and system for energy conservation in implantable stimulation devices
US7167750 *6 Jan 200423 Jan 2007Enteromedics, Inc.Obesity treatment with electrically induced vagal down regulation
US7180760 *12 Apr 200520 Feb 2007Advanced Neuromodulation Systems, Inc.Method of efficiently performing fractional voltage conversion and system comprising efficient fractional voltage converter circuitry
US7212865 *25 May 20041 May 2007Philip CoryNerve stimulator and method
US7324852 *25 Feb 200529 Jan 2008Giancarlo BarolatSystem and method for neurological stimulation of peripheral nerves to treat low back pain
US7326181 *1 Mar 20045 Feb 2008Jefferson Jacob KatimsNervous tissue stimulation device and method
US7333857 *16 Jul 200419 Feb 2008Arcl, Inc.Treatment of pain
US7337005 *7 Sep 200526 Feb 2008Spinal Modulations, Inc.Methods for stimulating a nerve root ganglion
US7346398 *23 Sep 200418 Mar 2008Bio Control Medical (B.C.M.) Ltd.Electrode assembly for nerve control
US7349743 *28 Apr 200425 Mar 2008Advanced Neuromodulation Systems, Inc.System, method, and resilient neurological stimulation lead for stimulation of a person's nerve tissue
US7363076 *18 Jun 200422 Apr 2008Palo Alto InvestorsTreatment of conditions through modulation of the autonomic nervous system
US7483747 *15 Jul 200527 Jan 2009Northstar Neuroscience, Inc.Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US7493172 *4 Mar 200517 Feb 2009Boston Scientific Neuromodulation Corp.Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
US7502652 *23 Jan 200610 Mar 2009Rehabtronics, Inc.Method of routing electrical current to bodily tissues via implanted passive conductors
US7676269 *29 Dec 20039 Mar 2010Palo Alto InvestorsTreatment of female fertility conditions through modulation of the autonomic nervous system
US7689289 *22 Mar 200630 Mar 2010Medtronic, Inc.Technique for adjusting the locus of excitation of electrically excitable tissue with paired pulses
US7877136 *28 Sep 200725 Jan 2011Boston Scientific Neuromodulation CorporationEnhancement of neural signal transmission through damaged neural tissue via hyperpolarizing electrical stimulation current
US7890176 *17 Jun 200515 Feb 2011Boston Scientific Neuromodulation CorporationMethods and systems for treating chronic pelvic pain
US7933654 *16 Dec 200326 Apr 2011Massachusetts Eye & Ear InfirmaryVestibular stimulator
US7937145 *11 Jun 20073 May 2011Advanced Neuromodulation Systems, Inc.Dynamic nerve stimulation employing frequency modulation
US8170675 *26 Sep 20111 May 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8224453 *12 Mar 200817 Jul 2012Advanced Neuromodulation Systems, Inc.Spinal cord stimulation to treat pain
US8355792 *13 Apr 201215 Jan 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8359103 *13 Apr 201222 Jan 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8423147 *26 Sep 201116 Apr 2013Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers
US8428748 *13 Apr 201223 Apr 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20020055779 *5 Mar 19979 May 2002Brian J. AndrewsNeural prosthesis
US20030120323 *27 Nov 200226 Jun 2003Meadows Paul M.Rechargeable spinal cord stimulator system
US20040015202 *13 Jun 200322 Jan 2004Chandler Gilbert S.Combination epidural infusion/stimulation method and system
US20040034394 *15 Aug 200319 Feb 2004Woods Carla MannImplantable generator having current steering means
US20040039425 *29 May 200326 Feb 2004Beverley Greenwood-Van MeerveldSpinal cord stimulation as treatment for functional bowel disorders
US20040073273 *6 Oct 200315 Apr 2004Gluckman Bruce J.Adaptive electric field modulation of neural systems
US20040249416 *12 Sep 20039 Dec 2004Yun Anthony JoonkyooTreatment of conditions through electrical modulation of the autonomic nervous system
US20050033381 *13 Sep 200410 Feb 2005John CarterElectro therapy method and apparatus
US20050038489 *14 Aug 200317 Feb 2005Grill Warren M.Electrode array for use in medical stimulation and methods thereof
US20050065575 *18 Aug 200424 Mar 2005Dobak John D.Dynamic nerve stimulation for treatment of disorders
US20050113882 *18 Nov 200426 May 2005Advanced Neuromodulation Systems, Inc.Electrical stimulation system, lead, and method providing reduced neuroplasticity effects
US20050119713 *30 Dec 20042 Jun 2005Whitehurst Todd K.Methods for implanting a spinal cord stimulator
US20050143789 *25 Feb 200530 Jun 2005Whitehurst Todd K.Methods and systems for stimulating a peripheral nerve to treat chronic pain
US20050149148 *10 Feb 20057 Jul 2005Medtronic, Inc.Apparatus and method for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US20050245978 *12 Apr 20053 Nov 2005Advanced Neuromodulation Systems, Inc.Systems and methods for precharging circuitry for pulse generation
US20060004422 *11 Mar 20055 Jan 2006Dirk De RidderElectrical stimulation system and method for stimulating tissue in the brain to treat a neurological condition
US20060030895 *7 Jul 20059 Feb 2006Simon Bruce JMethod for treating degenerative disc disease using noninvasive capacitively coupled electrical stimulation device
US20060041285 *3 Aug 200523 Feb 2006Johnson Robert GPortable unit for treating chronic pain
US20060074456 *26 Sep 20056 Apr 2006Advanced Neuromodulation Systems, Inc.Method of using spinal cord stimulation to treat gastrointestinal and/or eating disorders or conditions
US20060089691 *29 Apr 200527 Apr 2006Medtronic, Inc.Implantable medical lead with axially oriented coiled wire conductors
US20060095088 *20 Oct 20054 May 2006Dirk De RidderNew stimulation design for neuromodulation
US20060116742 *20 Oct 20051 Jun 2006Dirk De RidderSpinal cord stimulation to treat auditory dysfunction
US20070021803 *24 Jul 200625 Jan 2007The Foundry Inc.Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US20070032827 *8 Aug 20068 Feb 2007Katims Jefferson JMethod and apparatus for producing therapeutic and diagnostic stimulation
US20070039625 *14 Mar 200622 Feb 2007Medtronic, Inc.Regional therapies for treatment of pain
US20070060954 *27 Feb 200615 Mar 2007Tracy CameronMethod of using spinal cord stimulation to treat neurological disorders or conditions
US20070073353 *9 Jun 200629 Mar 2007Medtronic, Inc.Implantable medical device with electrodes on multiple housing surfaces
US20070073354 *26 Sep 200529 Mar 2007Knudson Mark BNeural blocking therapy
US20070106337 *31 Oct 200610 May 2007Electrocore, Inc.Methods And Apparatus For Treating Disorders Through Neurological And/Or Muscular Intervention
US20070150034 *9 Jun 200628 Jun 2007Medtronic, Inc.Implantable medical lead
US20080033511 *11 Jun 20077 Feb 2008Leptos Biomedical, Inc.Dynamic nerve stimulation employing frequency modulation
US20080103570 *31 Oct 20061 May 2008Medtronic, Inc.Implantable medical elongated member including intermediate fixation
US20090036945 *1 Aug 20085 Feb 2009Chancellor Michael BMethods and systems for achieving a physiological response by pudendal nerve stimulation and blockade
US20090054962 *27 Aug 200826 Feb 2009Baylis Medical Company Inc.Methods for treating the thoracic region of a patient's body
US20090076561 *2 Sep 200819 Mar 2009Cardiac Pacemakers, Inc.Systems and methods for avoiding neural stimulation habituation
US20090132010 *19 Nov 200721 May 2009Kronberg James WSystem and method for generating complex bioelectric stimulation signals while conserving power
US20100016929 *23 Sep 200921 Jan 2010Arthur ProchazkaMethod and system for controlled nerve ablation
US20100069993 *16 Sep 200818 Mar 2010Joshua GreenspanOccipital neuromodulation
US20100094375 *15 Dec 200915 Apr 2010Enteromedics Inc.Neural electrode treatment
US20110009919 *10 Jul 200913 Jan 2011Boston Scientific Neuromodulation CorporationMethod to enhance afferent and efferent transmission using noise resonance
US20110009923 *10 Jul 200913 Jan 2011Boston Scientific Neuromodulation CorporationSystem and method for reducing excitability of dorsal root fiber by introducing stochastic background noise
US20110022114 *19 Apr 201027 Jan 2011Navarro Rosa MSystem and method for treating pain with peripheral and spinal neuromodulation
US20120016437 *26 Sep 201119 Jan 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20120016438 *26 Sep 201119 Jan 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20120016439 *26 Sep 201119 Jan 2012Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers
US20120089200 *5 Oct 201112 Apr 2012Boston Scientifc Neuromodulation CorporationNeurostimulation system and method for providing therapy to patient with minimal side effects
US20130041425 *9 Jul 201214 Feb 2013Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US20130066411 *7 Sep 201214 Mar 2013James R. ThackerSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130096643 *4 Dec 201218 Apr 2013Nevro CorporationMulti-frequency neural treatments and associated systems and methods
US20130096644 *4 Dec 201218 Apr 2013Nevro CorporationMulti-frequency neural treatments and associated systems and methods
US20130110196 *21 Dec 20122 May 2013Nevro CorporationSelective high frequency spinal cord stimulation for inhibiting pain with reduced side effects, and associated systems and methods
US20130123879 *27 Dec 201216 May 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8170675 *26 Sep 20111 May 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8209021 *26 Sep 201126 Jun 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US825505729 Jan 200928 Aug 2012Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US835579213 Apr 201215 Jan 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US835910213 Apr 201222 Jan 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US835910313 Apr 201222 Jan 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US839655916 Feb 201212 Mar 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US842314726 Sep 201116 Apr 2013Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers
US842874813 Apr 201223 Apr 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US850990513 Apr 201213 Aug 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US85099069 Jul 201213 Aug 2013Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US855432614 Mar 20138 Oct 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8649874 *30 Nov 201111 Feb 2014Nevro CorporationExtended pain relief via high frequency spinal cord modulation, and associated systems and methods
US867633114 Mar 201318 Mar 2014Nevro CorporationDevices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
US869410822 Apr 20108 Apr 2014Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified controllers
US869410921 Dec 20128 Apr 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8712533 *22 Apr 201029 Apr 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US871878127 Dec 20126 May 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US871878214 Mar 20136 May 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US87684724 Dec 20121 Jul 2014Nevro CorporationMulti-frequency neural treatments and associated systems and methods
US87749264 Dec 20128 Jul 2014Nevro CorporationMulti-frequency neural treatments and associated systems and methods
US879298825 Sep 201329 Jul 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US879875410 Mar 20085 Aug 2014Venturi Group, LlcNeural blocking therapy
US880551930 Sep 201012 Aug 2014Nevro CorporationSystems and methods for detecting intrathecal penetration
US883824822 Apr 201016 Sep 2014Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection
US8843188 *18 Nov 201023 Sep 2014Case Western Reserve UniversityAdjustable nerve electrode
US8843210 *5 Sep 201223 Sep 2014ElectroCore, LLCNon-invasive vagal nerve stimulation to treat disorders
US88494105 Apr 201330 Sep 2014Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US886223925 Sep 201314 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US886819224 Jan 201421 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US887421714 Mar 201328 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US887422114 Mar 201328 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US887422224 Jan 201428 Oct 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US888017724 Jan 20144 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US888632624 Jan 201411 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US888632724 Jan 201411 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US88863286 Mar 201411 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US889220925 Sep 201318 Nov 2014Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US89299865 Nov 20126 Jan 2015Nevro CorporationMedical device communication and charging assemblies for use with implantable signal generators, and associated systems and methods
US896548230 Sep 201024 Feb 2015Nevro CorporationSystems and methods for positioning implanted devices in a patient
US898361213 May 201417 Mar 2015Neuros Medical, Inc.High-frequency electrical nerve block
US89836246 Dec 200717 Mar 2015Spinal Modulation, Inc.Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
US898986514 Sep 201224 Mar 2015Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US900245915 Mar 20137 Apr 2015Boston Scientific Neuromodulation CorporationMethod for selectively modulating neural elements in the dorsal horn
US900246029 Jan 20147 Apr 2015Nevro CorporationDevices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
US904459229 Jan 20082 Jun 2015Spinal Modulation, Inc.Sutureless lead retention features
US905619727 Oct 200916 Jun 2015Spinal Modulation, Inc.Selective stimulation systems and signal parameters for medical conditions
US91017693 Jan 201211 Aug 2015The Regents Of The University Of CaliforniaHigh density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
US91802976 Mar 201410 Nov 2015Boston Scientific Neuromodulation CorporationSystem and method for spinal cord modulation to treat motor disorder without paresthesia
US918029824 Jan 201410 Nov 2015Nevro Corp.Extended pain relief via high frequency spinal cord modulation, and associated systems and methods
US92052615 Dec 20128 Dec 2015The Board Of Trustees Of The Leland Stanford Junior UniversityNeurostimulation methods and systems
US92482938 Sep 20142 Feb 2016Nevro CorporationDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified program selection
US9254386 *8 Jul 20139 Feb 2016Boston Scientific Neuromodulation CorporatitionSystem and method for modulating action potential propagation during spinal cord stimulation
US925956914 May 201016 Feb 2016Daniel M. BrounsteinMethods, systems and devices for neuromodulating spinal anatomy
US9278215 *14 Mar 20138 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US9283387 *14 Mar 201315 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US9283388 *14 Mar 201315 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US928961027 Aug 201222 Mar 2016Boston Scientific Neuromodulation CorporationFractionalized stimulation pulses in an implantable stimulator device
US9295839 *14 Mar 201329 Mar 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US929584022 Jan 201429 Mar 2016Nevro CorporationSystems and methods for automatically programming patient therapy devices
US929584112 Mar 201529 Mar 2016Meuros Medical, Inc.High-frequency electrical nerve block
US930802210 Dec 201212 Apr 2016Nevro CorporationLead insertion devices and associated systems and methods
US93146186 Dec 200719 Apr 2016Spinal Modulation, Inc.Implantable flexible circuit leads and methods of use
US93271102 Feb 20123 May 2016St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”)Devices, systems and methods for the targeted treatment of movement disorders
US9327121 *7 Sep 20123 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US932712524 Apr 20143 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US932712610 Oct 20143 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US932712727 Oct 20143 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US932712828 Oct 20143 May 2016Boston Scientific Neuromodulation CorporationAutomatic anode and cathode fractional control and location to selectively avoid dorsal root stimulation
US933335730 Sep 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US933335830 Sep 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US933335930 Sep 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US9333360 *10 Oct 201410 May 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US933336130 Oct 201410 May 2016Boston Scientific Neuromodulation CorporationSystem and method to automatically incorporate lead information from medical image into programmable user interface
US933965528 Jun 201317 May 2016Boston Scientific Neuromodulation CorporationSystem and method for compounding low-frequency sources for high-frequency neuromodulation
US934589115 Jan 201524 May 2016Nevro CorporationSystems and methods for positioning implanted devices in a patient
US93583888 Jul 20147 Jun 2016Nevro CorporationSystems and methods for detecting intrathecal penetration
US935839630 Oct 20147 Jun 2016Boston Scientific Neuromodulation CorporationSystems and methods for delivering sub-threshold therapy to a patient at a physiological midline
US936466120 Aug 201414 Jun 2016Case Western Reserve UniversityAdjustable nerve electrode
US938135921 Jan 20155 Jul 2016Boston Scientific Neuromodulation CorporationSystem and method for delivering modulated sub-threshold therapy to a patient
US938136020 Jan 20155 Jul 2016Boston Scientific Neuromodulation CorporationSystem and method for delivering modulated sub-threshold therapy to a patient
US9387327 *23 Oct 201412 Jul 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US939340913 Nov 201219 Jul 2016Neuroenabling Technologies, Inc.Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function
US939342311 Jul 201419 Jul 2016Boston Scientific Neuromodulation CorporationFractionalized stimulation pulses in an implantable stimulator device
US940301310 Sep 20142 Aug 2016Nevro CorporationSystems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US94030204 Oct 20122 Aug 2016Nevro CorporationModeling positions of implanted devices in a patient
US940901130 Jun 20149 Aug 2016California Institute Of TechnologyMethod of constructing an implantable microelectrode array
US94090199 Feb 20159 Aug 2016Nevro CorporationLinked area parameter adjustment for spinal cord stimulation and associated systems and methods
US940902012 May 20159 Aug 2016Nevro CorporationImplanted pulse generators with reduced power consumption via signal strength/duration characteristics, and associated systems and methods
US940902129 May 20159 Aug 2016St. Jude Medical Luxembourg Holdings SMI S.A.R.L.Selective stimulation systems and signal parameters for medical conditions
US940902326 Mar 20129 Aug 2016California Institute Of TechnologySpinal stimulator systems for restoration of function
US941521813 Nov 201216 Aug 2016The Regents Of The University Of CaliforniaTranscutaneous spinal cord stimulation: noninvasive tool for activation of locomotor circuitry
US94275706 Dec 200730 Aug 2016St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”)Expandable stimulation leads and methods of use
US94687625 Feb 201518 Oct 2016St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”)Pain management with stimulation subthreshold to paresthesia
US948084227 Oct 20141 Nov 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US948663330 Nov 20158 Nov 2016The Board Of Trustees Of The Leland Stanford Junior UniversitySelective stimulation to modulate the sympathetic nervous system
US95173441 Mar 201613 Dec 2016Nevro CorporationSystems and methods for selecting low-power, effective signal delivery parameters for an implanted pulse generator
US9592388 *22 Apr 201014 Mar 2017Nevro Corp.Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection
US95975171 Jul 201521 Mar 2017Boston Scientific Neuromodulation CorporationNeurostimulation system with flexible patterning and waveforms
US959752121 Jan 201521 Mar 2017Bluewind Medical Ltd.Transmitting coils for neurostimulation
US960405919 Feb 201528 Mar 2017Nevro Corp.Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
US961623012 Dec 201411 Apr 2017Boston Scientific Neuromodulation CorporationSystems and methods for programming a neuromodulation system
US962323326 Feb 201518 Apr 2017St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”)Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
US962325026 Jun 201418 Apr 2017Boston Scientific Neuromodulation CorporationElectrode selection for sub-threshold modulation therapy
US965608522 Sep 201523 May 2017Boston Scientific Neuromodulation CorporationSystems and methods for receiving user-provided selection of electrode lists
US966249522 Jul 201530 May 2017Boston Scientific Neuromodulation CorporationEnhanced dorsal horn stimulation using multiple electrical fields
US966921917 Nov 20156 Jun 2017Nevro Corp.Systems and methods for delivering neural therapy correlated with patient status
US96692215 May 20166 Jun 2017Boston Scientific Neuromodulation CorporationSystem to detect lead location from medical image
US966922212 Apr 20166 Jun 2017Boston Scientific Neuromodulation CorporationAutomatic anode and cathode fractional control and location to selectively avoid dorsal root stimulation
US9694183 *6 Mar 20144 Jul 2017Boston Scientific Neuromodulation CorporationNeuromodulation system and method for providing multiple modulation patterns in a single channel
US971370712 Nov 201525 Jul 2017Bluewind Medical Ltd.Inhibition of implant migration
US973113322 Jan 201415 Aug 2017Nevro Corp.Systems and methods for systematically testing a plurality of therapy programs in patient therapy devices
US973771522 Sep 201522 Aug 2017Boston Scientific Neuromodulation CorporationPerception calibration of neural tissue using field troll
US973771714 Sep 201522 Aug 2017Boston Scientific Neuromodulation CorporationGraphical user interface for programming neurostimulation pulse patterns
US976414122 Sep 201519 Sep 2017Boston Scientific Neuromodulation CorporationNeuromodulation with burst stimulation
US976414621 Jan 201519 Sep 2017Bluewind Medical Ltd.Extracorporeal implant controllers
US977600222 Dec 20143 Oct 2017Nevro Corp.Medical device communication and charging assemblies for use with implantable signal generators, and associated systems and methods
US977600612 Jul 20163 Oct 2017Nevro Corp.Systems and methods for adjusting electrical therapy based on impedance changes
US978258910 Jun 201510 Oct 2017Bluewind Medical Ltd.Implantable electrostimulator for improving blood flow
US978259314 Jul 201610 Oct 2017Boston Scientific Neuromodulation CorporationFractionalized stimulation pulses in an implantable stimulator device
US980205229 Oct 201531 Oct 2017Boston Scientific Neuromodulation CorporationMethod and apparatus for programming complex neurostimulation patterns
US981488022 Sep 201514 Nov 2017Boston Scientific Neuromodulation CorporationShort pulse width stimulation
US98148845 Nov 201214 Nov 2017Nevro Corp.Systems and methods for detecting faults and/or adjusting electrical therapy based on impedance changes
US20070073354 *26 Sep 200529 Mar 2007Knudson Mark BNeural blocking therapy
US20080140152 *6 Dec 200712 Jun 2008Spinal Modulation, Inc.Implantable flexible circuit leads and methods of use
US20080140169 *6 Dec 200712 Jun 2008Spinal Modulation, Inc.Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
US20090319013 *19 May 200924 Dec 2009Boling C LanceImplantable neural stimulation electrode assemblies and methods for stimulating spinal neural sites
US20100274312 *22 Apr 201028 Oct 2010Konstantinos AlatarisSpinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
US20100274314 *22 Apr 201028 Oct 2010Konstantinos AlatarisSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20100274317 *22 Apr 201028 Oct 2010Jon ParkerDevices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection
US20100292769 *14 May 201018 Nov 2010Brounstein Daniel MMethods, systems and devices for neuromodulating spinal anatomy
US20110125216 *18 Nov 201026 May 2011Case Western Reserve UniversityAdjustable nerve electrode
US20120016437 *26 Sep 201119 Jan 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20120016438 *26 Sep 201119 Jan 2012Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20120172946 *30 Nov 20115 Jul 2012Konstantinos AlatarisExtended pain relief via high frequency spinal cord modulation, and associated systems and methods
US20130066411 *7 Sep 201214 Mar 2013James R. ThackerSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130144359 *29 Jan 20136 Jun 2013Eyad KishawiPain management with stimulation subthreshold to paresthesia
US20130204323 *14 Mar 20138 Aug 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130204324 *14 Mar 20138 Aug 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130238050 *5 Sep 201212 Sep 2013ElectroCore, LLC.Non-invasive vagal nerve stimulation to treat disorders
US20130261695 *14 Mar 20133 Oct 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130261696 *14 Mar 20133 Oct 2013Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20130296975 *8 Jul 20137 Nov 2013Boston Scientific Neuromodulation CorporationSystem and method for modulating action potential propagation during spinal cord stimulation
US20140277267 *15 Mar 201418 Sep 2014Boston Scientific Neuromodulation CorporationNeuromodulation system and method for transitioning between programming modes
US20140277281 *6 Mar 201418 Sep 2014Boston Scientific Neuromodulation CorporationNeuromodulation system and method for providing multiple modulation patterns in a single channel
US20150032182 *10 Oct 201429 Jan 2015Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20150045853 *23 Oct 201412 Feb 2015Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160121119 *6 Nov 20155 May 2016Nevro Corp.Extended pain relief via high frequency spinal cord modulation, and associated systems and methods
US20160287872 *5 Apr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160287873 *5 Apr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160287874 *5 Apr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160287875 *6 Apr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US20160287888 *5 Apr 20166 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20160303374 *20 Apr 201620 Oct 2016Nevro CorporationSelective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20170021177 *6 Oct 201626 Jan 2017Boston Scientific Neuromodulation CorporationSpatially selective nerve stimulation in high-frequency nerve conduction block and recruitment
USD7363835 Nov 201211 Aug 2015Nevro CorporationImplantable signal generator
USD7369305 Apr 201318 Aug 2015Nevro CorporationImplantable signal generator
EP2709717A2 *18 May 201226 Mar 2014Neuros Medical, Inc.High-frequency electrical nerve block
EP2709717A4 *18 May 201222 Oct 2014Neuros Medical IncHigh-frequency electrical nerve block
EP2968945A4 *13 Mar 201430 Nov 2016Univ DukeSystems and methods for applying electrical stimulation for optimizing spinal cord stimulation
EP3225278A128 Mar 20174 Oct 2017Nevro Corp.Distributed electrode lead configurations and associated systems and methods
WO2012044695A2 *28 Sep 20115 Apr 2012Nevro CorporationSystems and methods for positioning implanted devices in a patient
WO2012044695A3 *28 Sep 20114 Oct 2012Nevro CorporationSystems and methods for positioning implanted devices in a patient
WO2015179177A1 *12 May 201526 Nov 2015Nevro CorporationImplanted pulse generators with reduced power consumption via signal strength/duration characteristics, and associated systems and methods
Classifications
U.S. Classification607/46
International ClassificationA61N1/34
Cooperative ClassificationA61N1/3787, A61N1/36171, A61N1/0551, A61N1/36071
European ClassificationA61N1/36Z3C, A61N1/36Z, A61N1/36E4
Legal Events
DateCodeEventDescription
24 Apr 2009ASAssignment
Owner name: NEVRO CORPORATION, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FANG, ZI-PING;CAPARSO, ANTHONY V.;ERICKSON, BRIAN J.;REEL/FRAME:022595/0574;SIGNING DATES FROM 20090115 TO 20090205
13 Aug 2012ASAssignment
Owner name: NEVRO CORPORATION, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALATARIS, KONSTANTINOS;WALKER, ANDRE B.;REEL/FRAME:028778/0861
Effective date: 20120813
12 Dec 2014ASAssignment
Owner name: CAPITAL ROYALTY PARTNERS II L.P., TEXAS
Free format text: SECURITY INTEREST;ASSIGNOR:NEVRO CORP.;REEL/FRAME:034619/0546
Effective date: 20141212
Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.
Free format text: SECURITY INTEREST;ASSIGNOR:NEVRO CORP.;REEL/FRAME:034619/0546
Effective date: 20141212
Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Free format text: SECURITY INTEREST;ASSIGNOR:NEVRO CORP.;REEL/FRAME:034619/0546
Effective date: 20141212
13 Jun 2016ASAssignment
Owner name: CRG SERVICING LLC,, TEXAS
Free format text: ASSIGNMENT AGREEMENT (REAFFIRMATION);ASSIGNORS:CAPITAL ROYALTY PARTNERS II L.P.;CAPITAL ROYALTY PARTNERS II - PARALLEL FUND;PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.;REEL/FRAME:038984/0865
Effective date: 20160613
Owner name: CRG SERVICING LLC,, TEXAS
Free format text: ASSIGNMENT AGREEMENT (REAFFIRMATION);ASSIGNORS:CAPITAL ROYALTY PARTNERS II L.P.;CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.;PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.;REEL/FRAME:038984/0865
Effective date: 20160613
27 Jun 2016ASAssignment
Owner name: NEVRO CORP., CALIFORNIA
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CRG SERVICING LLC;REEL/FRAME:039168/0890
Effective date: 20160613